Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of April 2026
Key Event: Issuance of a press release on April 30, 2026, regarding positive Phase 2a clinical data for the drug candidate Namodenoson in the treatment of pancreatic cancer.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements or quantitative financial data.
Material Changes
The primary material change reported is the clinical progress of Namodenoson in pancreatic cancer:
- Phase 2a Data: Positive results reported.
- Patient Retention: 35% of patients remained on therapy.
- Durability: At least one patient remained on therapy beyond 16 months.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates the first four paragraphs of the April 30, 2026 press release by reference into the company's Registration Statements (Forms S-8 and F-3).
Outlook: The positive data suggests potential therapeutic efficacy, though specific future guidance or timelines are not detailed in this summary text.
Risks: No specific risks or contingencies are detailed in the provided text beyond the inherent uncertainties of clinical development implied by the Phase 2a status.
Key Facts for Investor Verification
- Verify the full details of the Phase 2a clinical trial design and statistical significance in the attached Exhibit 99.1 (Press Release).
- Confirm the total number of patients enrolled in the study to contextualize the "35% remaining on therapy" metric.
- Review the company's cash runway and capital requirements, as this filing does not disclose current liquidity levels.
- Check subsequent filings for any regulatory feedback or updated timelines following the April 30, 2026 announcement.